Generate Biomedicines, Inc.
GENBUnited States
2 filed reports · 137 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
2 reports · Mar 2026 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 2 | 337 | Mar 2026 to Jun 2026 |
Financial data
137 concepts · 337 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial137 concepts · 337 facts · Dec 2024 to Jul 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value4 · Mar 2025 to Jun 2026
- Allocated share based compensation expense4 · Mar 2025 to Jun 2026
- Cash and cash equivalents at carrying value4 · Mar 2025 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations4 · Mar 2025 to Jun 2026
- Comprehensive income net of tax4 · Mar 2025 to Jun 2026
- Comprehensive income net of tax attributable to noncontrolling interest4 · Mar 2025 to Jun 2026
- Comprehensive income net of tax including portion attributable to noncontrolling interest4 · Mar 2025 to Jun 2026
- Depreciation and amortization4 · Mar 2025 to Jun 2026
- Depreciation nonproduction4 · Mar 2025 to Jun 2026
- Earnings per share basic4 · Mar 2025 to Jun 2026
- Earnings per share diluted4 · Mar 2025 to Jun 2026
- External - discovery related costs and other4 · Mar 2025 to Jun 2026
- External - General and administrative4 · Mar 2025 to Jun 2026
- Fair value adjustment of warrants4 · Mar 2025 to Jun 2026
- Foreign currency transaction gain loss before tax4 · Mar 2025 to Jun 2026
- General and administrative expense (US GAAP)4 · Mar 2025 to Jun 2026
- General and administrative personnel-related (excluding stock-based compensation)4 · Mar 2025 to Jun 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest4 · Mar 2025 to Jun 2026
- Income tax expense benefit4 · Mar 2025 to Jun 2026
- Interest expense nonoperating4 · Mar 2025 to Jun 2026
- Investment income interest4 · Mar 2025 to Jun 2026
- Net income loss4 · Mar 2025 to Jun 2026
- Net income loss attributable to noncontrolling interest4 · Mar 2025 to Jun 2026
- Net income loss available to common stockholders basic4 · Mar 2025 to Jun 2026
Segments
Figures broken down by business line, region, product or another axis the company reports on.
No segment breakdowns.
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 17, 2026) and refreshed every few hours.